雌激素和孕激素受体在粉刺性乳痈的表达及意义

目的:探讨粉刺性乳痈患者雌激素受体(ER)、孕激素受体(PR)的表达及临床意义。方法:选择我院2017年1月～2018年12月收治的80例粉刺性乳痈患者,采用免疫组化法检测其乳腺病变组织ER、PR的表达,酶联免疫吸附法(ELISA)检测血清白介素-1β(interleukin-1β, IL-1β)、IL-6及肿瘤坏死因子-α(tumor necrosis factor-α, TNF-α)水平,分析乳腺病变组织ER、PR的表达与血清IL-1β、IL-6、TNF-α水平的相关性。结果:与普通乳腺炎组、乳腺导管扩张组比较,肉芽肿组、脓肿组血清IL-1β、IL-6、TNF-α水平明显升高,与肉芽肿组比较,脓肿组血清IL-1β、IL-6、TNF-α水平亦明显升高(P0.05)。普通乳腺炎组、乳腺导管扩张组血清IL-1β、IL-6、TNF-α水平比较差异无统计学意义(P0.05)。普通乳腺炎组、乳腺导管扩张组、肉芽肿组、脓肿组ER、PR的表达水平依次降低(P0.05)。普通乳腺炎组、乳腺导管扩张组ER、PR的表达与血清IL-1β、IL-6水平均呈显著负相关,而与血清TNF-α水平无显著相关性(P0.05);肉芽肿组、脓肿组ER、PR表达与血清IL-1β、IL-6、TNF-α水平均呈显著负相关(P0.05)。结论:粉刺性乳痈患者ER、PR呈低表达或失表达,且与炎症因子及病情严重程度具有良好相关性。     

pSTAT3和SOCS3在人乳腺癌组织中的表达及意义

目的 研究激活STAT3( pSTAT3)蛋白和SOCS3在人乳腺癌和乳腺良性病变组织中的蛋白表达及其临床意义.方法 应用免疫组织化学检测160例乳腺癌和36例乳腺良性病变组织pSTAT3和SOCS3蛋白的表达情况,分析它们与患者临床病理特征的关系.结果 人乳腺癌组织中pSTAT3和SOCS3蛋白表达阳性率分别为69.4％和40.0％,乳腺良性病变组织中pSTAT3和SOCS3蛋白表达阳性率分别为33.3％和22.2％,前者与后者相比具有统计学意义(P＜0.01和P＜0.05);乳腺癌pSTAT3蛋白表达与肿瘤的大小、淋巴结转移和临床分期均呈显著正相关(均P＜0.01),但与患者年龄、肿瘤的组织学分级、雌孕激素受体表达和c-erBb-2表达均无显著相关(均P＞0.05);SOCS3蛋白表达与肿瘤大小呈显著正相关(P＜0.05),但与患者年龄、淋巴结转移、临床分期、肿瘤的组织学分级、雌孕激素受体表达和c-erBb-2表达均无显著相关(均P＞0.05);乳腺癌pSTAT3和SOCS3表达呈显著正相关(r=0.237,P＜0.01).结论 乳腺癌pSTAT3和SOCS3表达状况与肿瘤生长、侵袭和转移等呈密切相关,提示STAT3和SOCS3可能在乳腺癌发生发展过程中发挥了重要作用.     

浆细胞性乳腺炎组织中IL-1β及TNF-α的表达及临床意义

目的:研究浆细胞性乳腺炎(PCM)组织中白细胞介素-1β(IL-1β)及肿瘤坏死因子-α(TNF-α)的表达及其临床意义。方法:选择2013年11月到2016年4月在内蒙古自治区人民医院就诊的PCM患者50例作为观察组,选择上述观察组患者中距炎性肿物边缘3cm且镜检为正常乳腺组织23例作为对照组,比较两组组织中IL-1β及TNF-α的表达,分析不同临床分期和分型者IL-1β及TNF-α的表达及相关性。结果:观察组组织中的IL-1β及TNF-α的表达水平均分别明显高于对照组差异有统计学意义(P0.05);观察组急性期及亚急性期的患者IL-1β及TNF-α水平分别明显高于慢性期,且急性期明显高于亚急性期,差异均有统计学意义(P0.05);不同临床分型者的IL-1β及TNF-α水平相比差异均无统计学意义(P0.05),依照PEARSON法分析相关性发现,观察组不同临床分期患者的IL-1β及TNF-α呈正相关(r=0.860,P=0.000)。结论:PCM组织中的IL-1β及TNF-α高表达,且两者对PCM的发展发挥了协同作用。     

原发性胆汁性肝硬化患者血清IL-6 水平与UDCA疗效的相关性研究

目的:观察原发性胆汁性肝硬化(primary biliary cirrhosis,PBC)患者治疗前后血清IL-6表达水平,探索其与熊去氧胆酸(Ursodeoxycholic acid,UDCA)疗效的临床相关性。方法:本研究回顾性纳入自2013年-2015年就诊于第四军医大学西京消化病医院的40例新诊断PBC患者,及40例健康对照者。收集PBC患者治疗前后的相关临床资料和血清样本,采用ELISA方法检测患者血清IL-6表达水平,并进一步分析其临床意义。结果:1)治疗前PBC患者血清IL-6表达水平明显高于健康对照者(P0.001);2)PBC患者在接受UDCA治疗后的第3,6和12个月血清IL-6水平与治疗前相比明显降低(P0.05),且在第3个月时下降最明显。3)无论是依据Paris I标准还是Barcelona标准,结果显示,UDCA应答者与应答不佳者相比其治疗前血清IL-6水平无统计学差异(P=0.373;P=0.409)。但UDCA应答者在治疗3个月时其血清IL-6表达水平比治疗前明显下降(P0.05),而应答不佳者治疗3个月时血清IL-6表达水平与治疗前相比无明显差异(P=0.667;P=0.186)。结论:IL-6可能在PBC发病的免疫机制中发挥着重要的作用。目前尚不能认为PBC患者治疗前血清IL-6表达水平能独立评价UDCA疗效,但是治疗三个月后患者血清IL-6水平下降趋势能够提示PBC患者对UDCA的应答情况。     

浆细胞性乳腺炎组织中IL-1beta及TNF-alpha的表达及临床意义

目的：研究浆细胞性乳腺炎（PCM）组织中白细胞介素-1beta（IL-1beta）及肿瘤坏死因子-alpha（TNF-alpha）的表达及其临床意义。方法：选 择2013 年11 月到2016 年4 月在内蒙古自治区人民医院就诊的PCM 患者50例作为观察组,选择上述观察组患者中距炎性肿 物边缘>3cm 且镜检为正常乳腺组织23例作为对照组,比较两组组织中IL-1beta及TNF-alpha的表达,分析不同临床分期和分型者 IL-1beta及TNF-alpha的表达及相关性。结果：观察组组织中的IL-1beta及TNF-alpha的表达水平均分别明显高于对照组,差异有统计学意义 （P<0.05）;观察组急性期及亚急性期的患者IL-1beta及TNF-alpha水平分别明显高于慢性期,且急性期明显高于亚急性期,差异均有统 计学意义（P<0.05）;不同临床分型者的IL-1茁及TNF-琢水平相比,差异均无统计学意义（P＞ 0.05）;依照PEARSON法分析相关性 发现,观察组不同临床分期患者的IL-1茁及TNF-琢呈正相关（r=0.860,P=0.000）。结论：PCM组织中的IL-1beta及TNF-alpha高表达,且 两者对PCM 的发展发挥了协同作用。     

包虫病患者血清中可溶性Tim3/Galectin9水平的表达及临床意义

目的:研究包虫病患者血清中可溶性T细胞免疫球蛋白及黏蛋白分子3(Tim3)/半乳糖凝集素9(Galectin9)水平的表达及临床意义。方法:选取2015年2月至2016年12月于我院接受治疗的包虫病患者40例作为包虫病组,另选取同期于我院接受体检的健康志愿者40例作为健康对照组,采用酶联免疫吸附法检测两组人员的血清Tim3、Galectin9、γ-干扰素(IFN-γ)、肿瘤坏死因子-α(TNF-α)、白细胞介素-4(IL-4)、白细胞介素-6(IL-6)水平,并分析包虫病患者血清Tim3、Galectin9水平与IFN-γ、TNF-α、IL-4、IL-6之间的相关性。结果:包虫病组患者血清Tim3、Galectin9水平均明显高于健康对照组(P0.05)。包虫病组患者血清IFN-γ、TNF-α较健康对照组明显更低,而IL-4、IL-6水平较健康对照组明显更高(P0.05)。经Pearson相关性分析可得:包虫病患者血清Tim3、Galectin9水平与血清IFN-γ、TNF-α均呈负相关关系,而与IL-4、IL-6水平均呈正相关关系(P0.05)。结论:包虫病患者血清可溶性Tim3/Galectin9水平异常升高,其主要作用机制可能与影响细胞因子IFN-γ、TNF-α、IL-4、IL-6水平变化有关,在包虫病的发生、发展过程中起着重要的作用。     

沙眼衣原体持续感染对Hela细胞TLR4/IL-6/STAT3信号通路的影响

目的：分析沙眼衣原体（Chlamydia trachomatis,Ct）持续感染对靶细胞TLR4/IL-6/STAT3信号通路的影响.方法：利用Hela细胞分别建立Ct急性感染及持续性感染模型,通过qRT-PCR、ELISA等方法比较Ct感染过程中靶细胞TLR4、STAT3、IL-6转录水平及细胞因子IL-6分泌量的变化.结果：Ct感染后靶细胞TLR4、IL-6、STAT3转录水平及细胞因子IL-6分泌量均呈现时间相关性上调,且持续性感染状态下比急性感染状态下的上调更为显著;IL-6/STAT3的表达量与TLR4转录水平正相关.结论：Ct持续感染过程中TLR4 的持续活化可大幅上调IL-6/STAT3信号通路表达,可能参与了Ct持续感染后慢性炎性损伤过程.     

紫草素调节IL-6/STAT3信号通路对牙髓炎大鼠牙髓组织损伤的影响

摘要 目的：探究紫草素（SHI）调节白细胞介素（IL）-6/信号转导子和转录激活子3（STAT3）信号通路对牙髓炎大鼠牙髓组织损伤的影响及机制。方法：建立牙髓炎大鼠模型。实验分为对照组（Control组）、模型组（Model组）、SHI低、中、高剂量组（SHI-L、SHI-M、SHI-H组,0.125 mg/kg/d、0.25 mg/kg/d、0.5 mg/kg/d SHI）、SHI高剂量+STAT3激动剂Colivelin组（SHI-H+Colivelin组,0.5 mg/kg/d SHI+1 mg/kg/d Colivelin）,每组18只。观察大鼠一般行为变化;酶联免疫吸附法（ELISA）检测血清IL-6、IL-1β、肿瘤坏死因子α（TNF-α）、CXC趋化因子配体10（CXCL10）、血管内皮生长因子（VEGF）水平。苏木精-伊红（HE）染色观察牙髓组织病理变化;免疫组化法检测牙髓组织IL-6表达;免疫印迹法检测IL-6/STAT3信号通路相关蛋白表达。结果：与Control组相比,Model组大鼠饮食减少,不敢咬食物,精神萎靡;牙髓组织出现坏死,牙本质细胞排列紊乱,炎性细胞浸润及纤维组织增加,根髓充血扩张;血清IL-6、IL-1β、TNF-α、CXCL10和VEGF水平,IL-6平均光密度及IL-6和JAK2蛋白水平、p-STAT3/STAT3水平显著增加（P<0.05）。与Model组相比,SHI-L、SHI-M和SHI-H组大鼠饮食较正常,精神状态较佳,牙髓组织病理变化减轻;血清IL-6、IL-1β、TNF-α、CXCL10和VEGF水平,IL-6平均光密度及IL-6和JAK2蛋白水平、p-STAT3/STAT3水平逐渐降低（P<0.05）。与SHI-H组相比,SHI-H+Colivelin组大鼠饮食较差,精神不佳,牙髓组织病变加重;血清IL-6、IL-1β、TNF-α、CXCL10和VEGF水平,IL-6平均光密度及IL-6和JAK2蛋白水平、p-STAT3/STAT3水平显著增加（P<0.05）。结论：SHI能抑制牙髓炎大鼠炎症水平,减轻牙髓组织损伤,其机制可能与抑制IL-6/STAT3信号通路有关。     

蒲公英多糖对溃疡性结肠炎大鼠IL-6/STAT3信号通路的影响

目的：观察蒲公英多糖对溃疡性结肠炎大鼠模型IL-6/STAT3信号通路的调控作用。方法：清洁级SD大鼠40只,雌雄各半,随机分为4组（n=10）：空白组、模型组、阳性对照组、蒲公英多糖组。采用2,4,6-三硝基苯磺酸（TNBS）诱导结肠炎大鼠模型,阳性对照组采用美沙拉嗪10 mg/kg·d灌胃,蒲公英多糖组采用蒲公英多糖10 mg/kg·d灌胃,治疗4周后处死,观察大鼠结肠粘膜病理改变,检测大鼠血清白介素-6（IL-6）含量、结肠髓过氧化物酶（MPO）、白介素-6受体（sIL-6Rα）、糖蛋白130（gp130）、转录活化因子3（STAT3）、IL-6 mRNA表达。结果：与正常组比较,模型组大鼠血清IL-6含量明显升高（P<0.01）,MPO阳性密度明显增高（P<0.01）,sIL-6Rα、gp130含量明显增高（P<0.01）,肠组织STAT3、IL-6 mRNA相对表达量明显增高（P<0.01）;与模型组比较蒲公英多糖组、美沙拉嗪组大鼠血清IL-6含量明显降低（P<0.01）,MPO阳性密度明显降低（P<0.01）,sIL-6Rα、gp130含量明显降低（P<0.01）,肠组织STAT3、IL-6 mRNA相对表达量与模型组比较明显降低（P<0.05）。结论：蒲公英多糖能够降低溃疡性结肠炎大鼠IL-6水平,下调IL-6/STAT3通路中sIL-6Rα、gp130蛋白表达量,进而下调大鼠肠组织STAT3、IL-6 mRNA的转录水平,缓解结肠组织的炎症状态,保护和修复粘膜组织,起到治疗溃疡性结肠炎的作用。     

抑郁症患者血清miR-135a、miR-221表达水平与认知功能、事件相关电位P300和炎症细胞因子的相关性分析

目的:探讨抑郁症患者血清微小核糖核酸(mi R)-135a、mi R-221表达水平与认知功能、事件相关电位P300和炎症细胞因子的相关性。方法:选择2019年1月至2021年1月我院收治的216例抑郁症患者(抑郁症组)和同期于我院体检的200例健康志愿者(对照组)。检测血清mi R-135a、mi R-221表达水平及白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)水平。采用蒙特利尔认知评估量表(MoCA)、简易精神状态检查量表(MMSE)评估认知功能。采用全功能肌电诱发电位仪检测P3潜伏期和P3波幅。Pearson相关性分析mi R-135a、mi R-221表达水平与MoCA评分、MMSE评分、IL-6,hs-CRP,TNF-α、P3潜伏期和P3波幅的相关性。结果:抑郁症组血清mi R-221表达水平、P3潜伏期,血清IL-6、hs-CRP、TNF-α水平高于对照组(P<0.05),mi R-135a表达水平、MMSE评分、MoCA评分、P3波幅低于对照组(P<0.05)。mi R-221表达水平与P3潜伏期,血清IL-6、hs-CRP、TNF-α水平呈正相关(P<0.05),与MMSE评分、MoCA评分、P3波幅呈负相关(P<0.05);mi R-135a表达水平与P3潜伏期,血清IL-6、hs-CRP、TNF-α水平呈负相关(P<0.05),与MMSE评分、MoCA评分、P3波幅呈正相关(P<0.05)。结论:抑郁症患者血清mi R-135a表达水平降低,mi R-221表达水平增高,mi R-135a低表达和mi R-221高表达与抑郁症患者认知功能降低、机体炎症反应有关。     

miR-451a targeting IL-6R activates JAK2/STAT3 pathway,thus regulates proliferation and apoptosis of multiple myeloma cells

Objectives:To investigate the effects of miR-451a targeting interleukin-6 (IL-6) on the proliferation and apoptosis of multiple myeloma (MM) cells and its potential mechanism via JAK2/STAT3 pathway.Methods:mRNA expression of miR-451a and IL-6R in the plasma of patients with MM and normal controls were determined by RT-qPCR. U266 cells were cultured, transfected with miR-451a mimics, the proliferative ability of U266 cells was determined by CCK-8. Potential targets of miR-451a were predicted with the biological software TargetScan, and the direct relationship between miR-451a and the target IL-6R was analyzed by a dual-luciferase reporter assay. U266 cells were stimulated with IL-6R (100 ng/ml), and the proliferative ability and apoptosis rate were determined by CCK-8 and flow cytometry after 48h.Results:In the plasma of patients with MM, miR-451a expression was low and IL-6R expression was high. miR-451a targeted and negatively regulated IL-6R. Overexpressing miR-451a inhibited the proliferation and promoted the apoptosis of U266 cells. IL-6R acting on U266 cells promoted the proliferation and inhibited the apoptosis of U266 cells. Overexpressing miR-451a inhibited the activation of JAK2/STAT3 pathway and down-regulating miR-451a promoted the activation of JAK2/STAT3 pathway.Conclusions:miR-451a targeting IL-6R activates JAK2/STAT3 pathway, thus regulates the proliferation and apoptosis in MM cells.     

Overexpression of microRNA-155 increases IL-21 mediated STAT3 signaling and IL-21 production in systemic lupus erythematosus

IntroductionInterleukin (IL)-21 is a key cytokine in autoimmune diseases such as systemic lupus erythematosus (SLE) by its regulation of autoantibody production and inflammatory responses. The objective of this study is to investigate the signaling capacity of IL-21 in T and B cells and assess its possible regulation by microRNA (miR)-155 and its target gene suppressor of cytokine signaling 1 (SOCS1) in SLE.MethodsThe signaling capacity of IL-21 was quantified by stimulating peripheral blood mononuclear cells (PBMCs) with IL-21 and measuring phosphorylation of STAT3 (pSTAT3) in CD4+ T cells, B cells, and natural killer cells. Induction of miR-155 by IL-21 was investigated by stimulating purified CD4+ T cells with IL-21 and measuring miR-155 expression levels. The functional role of miR-155 was assessed by overexpressing miR-155 in PBMCs from SLE patients and healthy controls (HCs) and measuring its effects on STAT3 and IL-21 production in CD4+ and CD8+ T cells.ResultsInduction of pSTAT3 in CD4+ T cells in response to IL-21 was significantly decreased in SLE patients compared to HCs (p < 0.0001). Further, expression levels of miR-155 were significantly decreased and SOCS1 correspondingly increased in CD4+ T cells from SLE patients. Finally, overexpression of miR-155 in CD4+ T cells increased STAT3 phosphorylation in response to IL-21 treatment (p < 0.01) and differentially increased IL-21 production in SLE patients compared to HCs (p < 0.01).ConclusionWe demonstrate that SLE patients have reduced IL-21 signaling capacity, decreased miR-155 levels, and increased SOCS1 levels compared to HCs. The reduced IL-21 signaling in SLE could be rescued by overexpression of miR-155, suggesting an important role for miR-155 in the reduced IL-21 signaling observed in SLE.

Electronic supplementary material

The online version of this article (doi:10.1186/s13075-015-0660-z) contains supplementary material, which is available to authorized users.     

BDNF/TrkB confers bortezomib resistance in multiple myeloma by inducing BRINP3

BackgroundThe proteasome inhibitor bortezomib (BTZ) has significantly improved the survival of multiple myeloma (MM) patients. However, most MM patients still relapse and have drug resistance after BTZ treatment.MethodssiRNA transfection was performed to knock down BDNF and TrkB expression. ELISA, western blot, quantitative polymerase chain reaction, CCK-8 assay, and flow cytometry analysis were performed to analyze the functions of BDNF/TrkB signaling in MM cells.ResultsWe identified a cell-autonomous mechanism that promotes BTZ resistance in MM, prolongs their RPMI 8226/BTZ resistant cell survival and optimizes their proliferating function. Specifically, RPMI 8226/BTZ cells produced the brain derived neurotrophic factor (BDNF) and its receptor TrkB, which served as a survival factor in the RPMI 8226/BTZ resistant environment. BDNF/TrkB induced phosphorylation of STAT3 that upregulated the bone morphogenetic protein/retinoic acid inducible neural-specific 3 (BRINP3).ConclusionsBDNF/TrkB enhanced downstream pathway expression of phosphorylation STAT3 and BRINP3 molecules, promoting RPMI 8226/BTZ cell proliferation and survival.General significanceThese data place BDNF/TrkB at the top of a pSTAT3-BRINP3 survival pathway and link adaptability to BTZ resistant conditions in MM disease.     

CCAAT/Enhancer binding protein delta (c/EBPdelta) regulation and expression in human mammary epithelial cells: I. "Loss of function" alterations in the c/EBPdelta growth inhibitory pathway in breast cancer cell lines

"Loss of function" alterations in growth inhibitory signal transduction pathways are common in cancer cells. In this study, we show that growth arrest (GA) treatments--serum and growth factor withdrawal and growth inhibitory IL-6 family cytokines (Interleukin-6 and Oncostatin M (OSM))--increase STAT3 phosphorylation (pSTAT3), increase CCAAT enhancer binding protein delta (C/EBPdelta) gene expression and induce GA of primary, finite-lifespan human mammary epithelial cells (HMECs), and immortalized breast cell lines (MCF-10A and MCF-12A). In contrast, serum and growth factor withdrawal from human breast cancer cell lines (MCF-7, SK-BR-3, T-47D, and MDA-MB-231) for up to 48 h induced a relatively modest increase in pSTAT3 levels and C/EBPdelta gene expression and resulted in varying levels of GA. In most breast cancer cell lines, IL-6 family cytokine treatment increased pSTAT3 levels and C/EBPdelta gene expression, however, growth inhibition was cell line dependent. In addition to "loss of function" alterations in growth inhibitory pathways, breast cancer cell lines also exhibit "gain of function" alterations in growth signaling pathways. The Akt growth/ survival pathway is constitutively activated in T-47D and MCF-7 breast cancer cells. The Akt inhibitor LY 294,002 significantly enhanced T-47D growth inhibition by serum and growth factor withdrawal or IL-6 family cytokine treatment. Finally, we show that activation of the pSTAT3/C/EBPdelta growth control pathway is independent of estrogen receptor status. These results demonstrate that "loss of function" alterations in the pSTAT3/C/EBPdelta growth inhibitory signal transduction pathway are relatively common in human breast cancer cell lines. Defective activation of the pSTAT3/ C/EBPdelta growth inhibitory signal transduction pathway, in conjunction with constitutive activation of the Akt growth stimulatory pathway, may play a synergistic role in the etiology or progression of breast cancer.